Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Posted by on Jun 28, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...

Read More

Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?

Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?

Posted by on Jun 27, 2020 in Prostate cancer | 0 comments

In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...

Read More

Evaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer

Evaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer

Posted by on Jun 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study looked at the long-term risk of secondary cancers following brachytherapy (BT; internal radiation therapy) for prostate cancer. It found that treating prostate cancer with BT had a low risk of secondary cancers. Some background Prostate cancer is a slow-growing cancer of the prostate gland. Men with prostate cancer that has...

Read More

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

Can vitamin D levels influence the chances of survival in patients with prostate cancer?

Can vitamin D levels influence the chances of survival in patients with prostate cancer?

Posted by on Jun 13, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined the levels of vitamin D in patients with prostate cancer (PC) to see if they were linked to patients’ chances of survival. The results showed that patients with higher levels of active vitamin D had a greater chance of survival. Some background Vitamin D is made from sun exposure and can be found in two...

Read More

Should androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?

Should androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?

Posted by on Jun 11, 2020 in Prostate cancer | 0 comments

In a nutshell The study looked at the sequence of dose-escalated radiotherapy (RT) and androgen-deprivation therapy (ADT) in the treatment of local prostate cancer (LPCa). The study found that treatment with ADT before RT had the same outcome as treatment with ADT and RT at the same time.  Some background LPCa is a form of cancer that is...

Read More

Does anti-clotting medication improve treatment results for patients with prostate cancer?

Does anti-clotting medication improve treatment results for patients with prostate cancer?

Posted by on Jun 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined if lower numbers of platelets (blood cells involved in forming clots) and anti-clotting medications were associated with treatment results in patients with prostate cancer (PC). The authors found that lower numbers of platelets and anti-clotting medication were associated with higher treatment...

Read More

Comparing cryosurgery and hormonal therapy for locally recurrent prostate cancer after radiotherapy

Comparing cryosurgery and hormonal therapy for locally recurrent prostate cancer after radiotherapy

Posted by on Jun 4, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared local cryosurgery (CRYO) against androgen deprivation therapy (ADT) for the treatment of locally recurring prostate cancer (LRPC). The study found local cryosurgery had a longer overall survival (OS) when compared to ADT. Some background LRPC is cancer that has re-occurred in the prostate gland...

Read More

Which therapy is more effective at boosting radiotherapy effectiveness for patients with localized prostate cancer?

Which therapy is more effective at boosting radiotherapy effectiveness for patients with localized prostate cancer?

Posted by on May 30, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared whether radiotherapy (RT) was more effective when combined with hormone therapy or brachytherapy (BT) for patients with localized prostate cancer (PC). The authors found that patients who received hormone therapy and RT survived for longer. Some background External beam radiotherapy (EBRT) focuses beams of...

Read More

Can bowel side effects caused by radiotherapy be reduced by a spacer tool in patients with prostate cancer?

Can bowel side effects caused by radiotherapy be reduced by a spacer tool in patients with prostate cancer?

Posted by on May 30, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined if a hydrogel spacer tool improved long-term quality of life for patients with prostate cancer (PC) who received radiotherapy (RT). The results showed that the spacer significantly reduced bowel side effects and improved patients’ quality of life. Some background RT is an effective therapy for patients with...

Read More